^
    Back
    Association details:
    Biomarker:AR expression + CYP17A1 expression
    Cancer:Prostate Cancer
    Drug:abiraterone acetate (CYP17A1 inhibitor)
    Direction:Resistant
    Evidence:
    Evidence Level:
    Resistant: C3 – Early Trials
    New
    Source:
    J Clin Oncol
    Title:

    Effects of Abiraterone Acetate on Androgen Signaling in Castrate-Resistant Prostate Cancer in Bone

    Excerpt:
    Homogeneous, intense nuclear expression of AR, combined with ≥ 10% CYP17 tumor expression, was correlated with longer time to treatment discontinuation (> 4 months) in 25 patients with tumor-infiltrated bone marrow samples.
    Secondary therapy:
    prednisone
    DOI:
    10.1200/JCO.2010.33.7675
    Trial ID:
    NCT00544440